An observational study in Heart Failure With Preserved Ejection Fraction (HFpEF), Atrial Fibrillation and Optic Nerve Sheath Diameter, sponsored by Ankara Ataturk Sanatorium Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 60 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Ankara Ataturk Sanatorium Training and Research Hospital · Observational
Among 55 studies in Atrial Fibrillation with a site in Turkey — 8 open to participants now, 9 under way, 2 of them phase 3. Atrial Fibrillation · Turkey.
Among the 55 studies in Atrial Fibrillation with a site in Turkey, this one is the 14th largest by enrollment of the 25 observational ones, is one of 5 that started in 2025, is one of 25 observational ones, and was the 51st registered.
4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
This study's enrollment of 309 is close to the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →8 of the 55 studies in Atrial Fibrillation with a site in Turkey are open now, in 12 countries. Each count lists the studies.
Of the 612 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 60 Years to 78 Years · all sexes · healthy volunteers too.
The full table on the hub →55 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2025.
Median enrollment 1,314 across the 30 interventional studies, 400 across the 25 observational. Of the 40 that completed or were terminated, 15 (38%) have results posted.
20 of 55 have an industry lead sponsor. The 10 most frequent:
Ankara Ataturk Sanatorium Training and Research Hospital is the lead sponsor of 38 studies on the registry; 15 are open to participants now.
Ankara Ataturk Sanatorium Training and Research Hospital has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
4 of the studies in Atrial Fibrillation with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07242326Kotyora Family Medicine Health Management and Education AssociationSNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye) | 2026-12-30 |
| NCT07877116Hüseyin Ulaş PinarSevoflurane Versus Propofol Anesthesia in Intracardiac Echocardiography-Guided Atrial Fibrillation Ablation | 2027-04 |
| NCT07808307Hande CörütTele-Rehabilitation After Catheter Ablation in Patients With Atrial Fibrillation | 2027-06 |
Among the 55 studies in Atrial Fibrillation with a site in Turkey, from their registry updates:
This study was designed to investigate predictors of atrial fibrillation (AF) in patients with heart failure with preserved ejection fraction (HFpEF), with a particular focus on the potential relationship between venous congestion and intracranial pressure dynamics. Among HFpEF patients, those with AF exhibited significantly higher right atrial pressure (RAP), larger right atrial area, higher CHA₂DS₂-VA scores, and increased optic nerve sheath diameter (ONSD), a noninvasive surrogate marker of intracranial pressure. In multivariable logistic regression analysis, increased ONSD, elevated RAP, larger right atrial area, and higher CHA₂DS₂-VA score remained independently associated with AF, suggesting that both systemic venous congestion and intracranial pressure-related mechanisms may contribute to AF susceptibility in this population. These findings support the hypothesis of a cardio-cerebral interaction in HFpEF, in which elevated right-sided filling pressures may impair cerebrospinal fluid drainage, increase intracranial pressure, and potentially promote AF through autonomic and hemodynamic pathways.
This study evaluates the association between atrial fibrillation (AF) and markers of systemic venous congestion and intracranial pressure in patients with heart failure with preserved ejection fraction (HFpEF). Using cranial MRI and echocardiographic assessment, optic nerve sheath diameter (ONSD), right atrial pressure (RAP), and atrial dimensions were analyzed as potential correlates of AF. Multivariable analysis demonstrated that increased ONSD, elevated RAP, larger right atrial area, and higher CHA₂DS₂-VA score were independently associated with AF. The findings support a potential pathophysiological link between venous congestion, intracranial pressure dynamics, and AF susceptibility in HFpEF, suggesting a possible cardio-cerebral interaction that may contribute to arrhythmogenesis and stroke risk.
A total of 309 subjects aged approximately 60-78 years with available cranial MRI data were enrolled, including a control group (n = 106), HFpEF patients in sinus rhythm (n = 111), and HFpEF patients with atrial fibrillation (n = 92).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged approximately 60-78 years with available cranial MRI , HFpEF patients in sinus rhythm, HFpEF patients with atrial fibrillation No HFpEF patients(control) -
Exclusion Criteria:
Patients with heart failure and reduced (EF \<50%), known intracranial hypertension, optic nerve or other neurological disorders, , goiter, liver cirrhosis, renal failure, severe valvular heart disease, congenital heart disease, and advanced diabetes mellitus requiring insulin therapy
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals without HFpEF or atrial fibrillation were used as the reference group.
Diagnostic Test: Echocardiography
HFpEF With Sinus Rhythm
Diagnostic Test: Echocardiography
HFpEF With Atrial Fibrillation
Diagnostic Test: Echocardiography
Standard transthoracic echocardiography, including EF, E/e', TRV, atrial areas, SPAP, and estimated right atrial pressure.
Atrial fibrillation status (AF vs sinus rhythm) in HFpEF patients
The primary analysis evaluates the association of ONSD, RAP, and the right atrial area with AF status.
Time frame: Baseline
Presence of atrial fibrillation in patients with HFpEF
The rhythm status was measured by electrocardiography and documented. The primary analysis evaluates the association of ONSD, RAP, and right atrial area with AF status.
Time frame: At baseline (cross-sectional assessment)
Plan to share: Yes — De-identified individual participant data will be available upon reasonable request for academic research purposes, subject to ethics committee approval and data protection policies.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Beginning 6 months after publication and ending 5 years after publication
Access criteria: Qualified researchers with a scientifically sound proposal may access de-identified IPD, the study protocol, SAP, and analytic code upon written request to the corresponding author, subject to ethics approval and data use agreement.
Data sharing details ↗ · sanatoryumdh.saglik.gov.tr
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Mar 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Ataturk Sanatorium Training and Research Hospital